Drug Trial Radar · NCT03651947
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Oct 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Aug 20, 2018
Primary completion
Nov 17, 2018
Study completion May 22, 2019
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Xgeva® in healthy adults.
Conditions
- Healthy People
Interventions
QL1206Drug
subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
Xgeva®Drug
subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve (AUC0-t )Time frame: 134 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.